Bank of America
FATE icon

Bank of America’s Fate Therapeutics FATE Stock Holding History

Bank of America’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,000
Closed -$124K – 7951
2022
Q2 		$124K Buy
5,000
+600
+14% +$16.6K ﹤0.01% 6369
2022
Q1 		$171K Buy
+4,400
New +$170K ﹤0.01% 6562

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's FATE Position: Q1 2026 in Review

Bank of America increased its Fate Therapeutics (FATE) stake by 25% in Q1 2026, buying an estimated $45.6K and bringing the position to 188,564 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #5302.

Bank of America first reported a position in FATE in Q4 2013 and has held it in 39 quarters since. The position peaked at $23M in Q2 2021. 158 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Bank of America held 188,564 shares of Fate Therapeutics worth $226K as of Q1 2026.
  • Bank of America bought 37,457 Fate Therapeutics shares in Q1 2026, an estimated $45.6K.
  • Fate Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5302 holding.
  • Bank of America first reported a position in Fate Therapeutics in Q4 2013 and has held it in 39 quarters since.
  • Bank of America's Fate Therapeutics position peaked at $23M in Q2 2021.
  • 158 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.